Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Liabilities and Shareholders Equity (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $366.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 40.49% to $366.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 1.31% year-over-year, with the annual reading at $366.3 million for FY2025, 40.49% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $366.3 million at Fulcrum Therapeutics, up from $214.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $366.3 million in Q4 2025, with the low at $137.9 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $247.6 million, with a median of $245.2 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 81.36% in 2021, then dropped 27.57% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $235.0 million in 2021, then fell by 3.54% to $226.7 million in 2022, then increased by 13.68% to $257.7 million in 2023, then rose by 1.17% to $260.7 million in 2024, then surged by 40.49% to $366.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $366.3 million, $214.9 million, and $228.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.